MedTrace Logo

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

NCT02277600 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-01-24

No results posted yet for this study

Summary

This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase the systemic exposure of BMS-626529.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

BMS-663068

DRUG

Darunavir

Darunavir

DRUG

Cobicistat

Cobicistat

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-05
Primary Completion
2015-01-12
Completion
2015-01-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02277600 on ClinicalTrials.gov